Abstract Alpha-linolenic acid (ALA), which is an omega-3 fatty acid from plant oils, has been reported to have beneficial effects on human brain health. However, the protective effect of ALA and its mechanism of action against amyloid beta (Ab)-mediated neurotoxicity, neuronal apoptosis and amyloid precursor protein (APP) processing are unclear. To investigate the neuroprotective effect of ALA, we treated Ab 25-35 -induced SH-SY5Y cells with ALA (1, 2.5, 5 and 25 lg/mL). In our results, Ab 25-35 -induced neuronal cell loss was observed, whereas ALA significantly increased the cell viability and decreased lactate dehydrogenase release. In addition, over-production of reactive oxygen species caused by Ab 25-35 was attenuated by treatment with ALA, and these inhibitory activities were mediated by regulation of the mitogen-activated protein kinase signaling pathway. Furthermore, our data shows that Ab 25-35 cause an increase in protein expression of APP-C-terminal fragment b, b-site APP-cleaving enzyme and presenilin-1 in SH-SY5Y cells, while ALA significantly down-regulated the expression of those amyloidogenic APP processing-related proteins. In addition, we confirmed that ALA enhanced a-secretase activity by upregulating the protein levels of A distintegrin and metalloprotease 10 and tumor necrosis factor-a-converting enzyme, indicating that ALA could promote non-amyloidogenic signaling pathways. ALA also significantly attenuated Ab 25-35 -induced neuronal apoptosis by up-regulation of the Bcl-2/Bax ratio. These findings suggest that ALA may be a beneficial agent for promoting prevention of Alzheimer's disease.
Introduction
Alzheimer's disease (AD) is characterized by abnormal accumulation of neurofibrillary tangles and senile plaques, resulting in neuronal dysfunction and death. The most important component of these plaques is amyloid beta (Ab), which is produced by amyloid precursor protein (APP) [1] . It was previously demonstrated that generation of Ab is mediated by two pathways: the amyloidogenic and non-amyloidogenic pathways. Cleavage of APP by b-and c-secretase leads to generation of amyloidogenic toxic Ab peptide. In an alternative pathway, APP proteolysis by asecretase generates soluble N-terminal fragment (sAPPa), which is non-toxic and neuroprotective with autocrine activity [2] [3] [4] . Thus, regulation of APP processing toward the non-amyloidogenic pathway is a therapeutic target for AD.
Accumulation of Ab could substantially increase the production of reactive oxygen species (ROS), thus stimulating oxidative stress and neuronal apoptosis via modulation of the mitogen-activated protein kinase (MAPK) signaling pathway [5, 6] . The MAPK family is composed of extracellular signal-regulated kinase 1/2 (ERK1/2), c-jun N-terminal kinase (JNK) and p38. The pathway of activated MAPK has been implicated in neuronal cell death in the brain of AD patients [7] . In addition, MAPK also plays a critical role in APP metabolism and Ab production [8] . It was demonstrated that MAPK promotes amyloidogenic/b-APP-cleavage versus non-amyloidogenic/a-APP-cleavage. Moreover, oxidative stress stimulates b-and c-secretase with activation of JNK and c-jun, thus promoting Ab production [9] .
Numerous studies have suggested that dietary n-3 polyunsaturated fatty acids (PUFAs) exert a beneficial effect on cognitive improvement via promotion of neuron survival [10] [11] [12] [13] . However, marine-derived eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are associated with toxicological effect or methyl mercury poisoning; thereby, a plant-derived PUFA, alpha-linolenic acid (ALA), is considered as the best alternative source [14] . Because ALA is an essential fatty acid, ALA must be obtained through dietary intake. In general, source of ALA includes green leafy vegetables and some nuts. In particular, ALA content is high in seed oils such as flaxseed (known as linseed), rapeseed, perilla and chia oil. Among the oils, perilla oil consistently contains the highest proportion of ALA, 54-64% [15] . Flaxseed oil also contains over 50% of ALA (average 53% of total fatty acids) [16] . Rapeseed oil and walnut oil contribute to the common dietary sources of ALA (10 and 9%, respectively) [17] . Administration of dietary ALA reduces neuronal cell death and improves cognitive function during natural aging with no side effects, suggesting that ALA has nutraceutical potential for treatment/prevention of neurodegenerative diseases [18] [19] [20] [21] . Consistent with these reports, we previously reported that administration of perilla oil and its major fatty acids, ALA, improved cognitive decline in an Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] -injected AD mouse model, having a comparable effect to that of DHA [22] . Although increasing evidences for ALA's effect on human health has been demonstrated, the underlying mechanisms by which ALA might influence neuronal cells against Ab remain to be established.
The current study describes the neuroprotective effect of ALA on Ab 25-35 -induced oxidative stress, neurotoxicity and neuronal apoptosis. Additionally, we investigated the modulation of APP processing in SH-SY5Y cells after ALA treatment.
Materials and methods

Preparation of sample
Perilla frutescens var. japonica oil was contributed by the Southern Area Crop Science, Rural Development Administration (Miryang, Republic of Korea). The fatty acid composition of perilla oil used in this study was ALA (515.20 mg/g), linoleic acid (141.16 mg/g), oleic acid (147.05 mg/g), stearic acid (23.08 mg/g) and palmitic acid (52.12 mg/g) [23] . ALA was obtained from perilla oil after treatment of urea with cooling by high-yield methods as described in previous study [24] . Before use, ALA was freshly prepared as a stock solution in dimethyl sulfoxide (DMSO), and final concentration adjusted by DMSO did not affect in cell viability. The ALA was stored in a refrigerator at 4°C with nitrogen gas for stability.
Instruments and reagents
Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , dichlorofluorescin diacetate (DCF-DA) and DMSO were supplied from Sigma Chemical Co. (St Louis, MO, USA). Dulbecco's modified Eagle's medium (DMEM), supplemented with penicillin/streptomycin and fetal bovine serum (FBS), was purchased from WelGENE (Daegu, Korea). Radioimmunoprecipitation assay (RIPA) buffer and protein marker were purchased from Elpis Biotech (Daejeon, Korea). In addition, 30% bis-acrylamide solution was purchased from Bio-Rad (Hercules, CA, USA). Polyvinylidene fluoride (PVDF) membrane was obtained from Millipore (Billerica, MA, USA).
Cell culture
SH-SY5Y human neuroblastoma cells were obtained from the KCLB (Korean Cell Line Bank, Seoul, Korea). The cells were maintained in a humidified atmosphere incubator at 37°C, 5% CO 2 and DMEM containing 1% penicillin/streptomycin and 10% FBS. Cell culture media were replaced with 0.05% trypsin-EDTA in phosphate-buffered saline (PBS).
After reaching confluent growth, the cells were seeded (5 9 10 4 cells/mL) into a 96-well plate and incubated overnight. After that, each concentration of ALA (1, 2.5, 5, and 25 lg/mL) was administered to cells for 2 h and Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (25 lM) was added. After incubation for 24 h, cell viability was determined by a previously described method, using the MTS solution (Promega, Madison, WI, USA) according to the manufacturer's instruction, and the absorbance of each well was read at 490 nm [25] .
Lactate dehydrogenase (LDH) release assay
According to the manufacturer's protocol, the LDH release was assessed by a LDH Cytotoxicity Detection Kit (Takara Bio, Shiga, Japan). SH-SY5Y cells were plated at a density of 5 9 10 4 cells/mL into a 96-well plate and incubated overnight. Cells were treated with ALA (1, 2.5, 5 and 25 lg/mL) for 2 h, and Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (25 lM) was added. After incubation for 24 h, the supernatant (100 lL) and reaction mix (100 lL) were added to a 96-well plate and incubated for 30 min at room temperature. All samples were measured for absorbance at 490 nm using a microplate reader [26] .
Measurement of ROS production
ROS scavenging property of cells after ALA treatment was measured using dichloro-dihydro-fluorescein diacetate (DCFH-DA). SH-SY5Y cells were seeded at a density of 5 9 10 4 cells/mL into a 96-well plate and incubated overnight. Cells were treated with ALA (5-25 lg/mL) for 2 h, and Ab 25-35 (25 lM) was added. After 24 h, the cells were incubated with 80 lM DCFH-DA at 37°C for 30 min, and then, florescence was monitored for 60 min, at wavelengths of 480 nm for excitation and 535 nm for emission, using a florescence plate reader (BMG LAB-TECH, Ortenberg, Germany) [27] .
Hoechst 33342 staining
SH-SY5Y cells were seeded on 8-well chamber slides and treated with ALA for 2 h. Cells were exposed to 25 lM 
Western blotting
SH-SY5Y cells were lysed according to the manufacturer's instructions using RIPA buffer containing 1 9 protease inhibitor cocktail (Sigma Co., St Louis, MO, USA). Proteins were separated by electrophoresis in 10-13% SDS-PAGE and blotted onto PVDF membranes. The membrane was blocked with 5% skim milk solution for 1 h at room temperature and then washed with PBS-T. The membrane was incubated overnight at 4°C with primary antibody [ERK, pERK1/2, JNK and pJNK (1:1000, Cell Signaling, Beverly, MA, USA); b-site APP-cleaving enzyme (BACE; 1:1000, Cell Signaling); presenilin-1 (PS1; 1:1000, Cell Signaling); anti-APP, C-terminal (1:1000; Sigma); a disintegrin and metalloprotease 10 (ADAM10; 1:200, Santa Cruz, CA, USA); tumor necrosis factor-a-converting enzyme (TACE; 1:200, Santa Cruz); Bcl-2 (1:200, Santa Cruz); Bax (1:200, Santa Cruz); and b-actin (1:200, Santa Cruz)]. After washing, the membrane was incubated with the appropriate HRP-conjugated secondary antibodies. Western bands were visualized using a chemiluminescent imaging system (Davinci Chemi, Seoul, Korea).
Statistical analysis
Results are expressed as mean ± SD. Statistical significance was determined by Student's t test analysis using the program IBM SPSS version 23. Significance was set at # P \ 0.05, ## P \ 0.01, * P \ 0.05 and ** P \ 0.01. # Significantly different from the control group; * significantly different from the Ab 25-35 -treated vehicle group.
Results
Effect of ALA on cell viability in Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] 
-induced SH-SY5Y cells
To examine the effect of ALA on SH-SY5Y cells induced by Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , the MTS assay was carried out. No significant effect on cell proliferation was observed when cells were 
Effect of ALA on ROS production in Ab 25-35 -induced SH-SY5Y cells
We investigated the inhibitory effect of ALA on ROS production in Ab 25-35 -treated SH-SY5Y cells. Figure 3 shows that Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] significantly increased ROS levels compared to that in the control group. However, ALA treatment inhibited ROS production. These findings suggest that ALA was able to attenuate oxidative stress by inhibiting ROS production, demonstrating its anti-oxidative effect in Ab 25-35 -induced SH-SY5Y cells.
Effect of ALA on ERK1/2 and JNK signaling pathway in Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] 
-induced SH-SY5Y cells
To examine the molecular mechanism involving MAPK activity after ALA treatment, western blot studies were performed. As shown in Fig. 4 , protein levels of pERK1/2 and pJNK were induced by Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , indicating that ERK1/2 and JNK MAPK signaling is associated with cell death in the presence of Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . However, ALA significantly inhibited phosphorylation of ERK1/2 and JNK. These results indicated that ALA might protect Ab 25-35 -induced ROS via modulation of the ERK1/2 and JNK signaling pathway. (Fig. 5) . However, ALA (especially at a concentration of 25 lg/mL) significantly inhibited those proteins compared to the vehicle group, indicating that ALA might reduce the production of Ab by down-regulation of amyloidogenic APP processing. Meanwhile, compared to the Ab 25-35 -treated group, treatment with ALA induced the non-amyloidogenic pathway by up-regulating the expression of ADAM10 and TACE, which are components of a-secretase (Fig. 6 ). These findings suggest that stimulating the non-amyloidogenic pathway in response to ALA may provide a neuroprotective effect against Ab. 
Discussion
A number of studies have shown that accumulation of Ab in the brain is strongly associated with oxidative stress, leading to neuronal cell death [28, 29] . Ab induces the generation of free radicals and was found to have a neurotoxic effect [30] . in this abnormal APP processing and Ab metabolism may be further reinforced by oxidative stress [31] [32] [33] . Recent studies have suggested that a possible strategy for AD prevention/treatment is the use of natural products [34] [35] [36] . Using natural sources is usually considered to be safer and have fewer side effects than chemically synthesized drugs. Dietary supplementation of n-3 PUFA, especially DHA, diminished Ab-induced neuronal toxicity and the amyloid plaque burden in vivo [37] . However, it remains uncertain whether ALA has a neuroprotective effect against Ab and the mechanism underlying this effect. The SH-SY5Y human neuroblastoma cells extensively have been used to evaluate the changes of neurotransmitter release, neuronal apoptosis and neurodegeneration, so as to mimic responses of neurons in experimental neuroscience research [38] . AD relates to high concentrations of the Ab, which causes apoptosis in neuronal cells [39] . Ab-induced neuronal damage in the SH-SY5Y cells is contributed to molecular signaling mechanisms that might be involved in the degeneration process of AD. The Ab initiates the APP processing, leading to activation of mitochondrial and extramitochondrial apoptotic pathway [40] . In the present study, we used SH-SY5Y neuronal cells treated with Ab to examine the role of ALA in regulating APP processing and neuronal apoptosis against Ab.
We have previously demonstrated that administration of perilla oil, which contains high levels of ALA, ameliorated cognitive decline in an Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] -injected mouse model [22] . In addition, treatment with perilla oil and ALA protected hydrogen peroxide-induced neuronal apoptosis through inactivation of caspase-9 and PARP and also up-regulated levels of Bcl-2 relative to Bax (not published). In this study, the protective effect and possible mechanism of ALA on Ab 25-35 -medicated oxidative stress, neuronal apoptosis and APP processing were examined. Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] treatment markedly decreased cell viability; however, ALA treatment significantly attenuated cell loss in SH-SY5Y induced by Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . This protective effect of ALA was also confirmed by LDH assay, as shown by significant inhibition of LDH release at ALA concentrations of 5 and 25 lg/ mL.
ROS production caused by Ab is known to be strongly associated with the senile plaques deposit in the brain of AD, resulting in neuronal cell death [41] . In agreement with this notion, we observed that treatment of Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] induced oxidative stress by generating ROS. In contrast, ALA scavenged the ROS to alleviate oxidative stress in cells induced with Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . During the progression of AD, the neuronal apoptosis response to ROS correlates with activation of MAPK signaling [42] . We further investigated whether ALA protects oxidative stress and neurotoxicity by modulating the MAPK pathway. Our results showed that Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] significantly increased phosphorylation of ERK1/2 and JNK, indicating that Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] induces neurotoxicity by activation of MAPK signaling. However, the activation of these kinases was significantly downregulated by ALA, suggesting that ALA is involved in the protective effect against Ab 25-35 -mediated ROS production and neurotoxicity through the ERK1/2 and JNK signaling pathway. In agreement with our findings, ALA also inhibited phosphorylation of MAPKs in lipopolysaccharide-induced RAW 264.7 cells [43] . Lee et al. [44] reported that inhibition of the ERK kinase pathway could enhance a-secretase, but inhibit b-and c-secretase activity, thereby inhibiting Ab formation. In addition, activation of JNK is involved in APP metabolism. Consistent with a role in JNK signaling, a previous study has demonstrated that inhibition of JNK activity is correlated with prevention of amyloidogenic cleavage of APP and reduction in Ab production [45] . We speculate that inhibition of pERK1/2 and pJNK may participate in APP processing.
APP undergoes two major metabolic pathways: the amyloidogenic and non-amyloidogenic pathways. Under normal physiological conditions, APP is mainly cleaved by a-secretase and then secretes sAPPa, which is a non-toxic Ab. However, APP cleaved by b-and c-secretases generates neurotoxic Ab [46] . Therefore, regulation of these enzymes (a, b and c) is a prominent target for treatment of AD. Recently, Amin et al. [47] demonstrated that treatment of Ab significantly elevated the protein expression levels of AD markers like APP and BACE in SH-SY5Y neuronal cells. Our results revealed that treatment with Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] significantly increased CTFb, BACE and PS1 protein expression levels, whereas ALA suppressed those levels in SH-SY5Y cells. This indicates that Ab-driven amyloidogenesis was blocked by ALA treatment. In contrast, ALA treatment increased expression of ADAM10 and TACE, which are considered to be the most likely candidates for asecretase, thereby inhibiting Ab production through induction of the non-amyloidogenic pathway. It has been shown that altered APP processing in SH-SY5Y cells exposed to chronic hypoxia resulted in decreased sAPPa levels together with down-regulation of ADAM10 and TACE protein expression [48] . Taken together, our findings suggest that enhancement of ADAM10 and TACE activity by ALA treatment supports the non-amyloidogenic route of APP metabolism.
The Ab treatment may result in neuronal cell death. In addition, neuronal apoptosis might be responsible for the accumulation of Ab, which would lead to increased apoptosis in neighboring neurons. Ab-induced neuronal cell death is associated with down-regulation of antiapoptotic Bcl-2 and with up-regulation of pro-apoptotic Bax protein expressions [49, 50] . In the present study, ALA treatment prevented SH-SY5Y cells from Ab 25-35 -induced neurotoxicity, as shown by a decline in apoptotic cell bodies in Hoechst 33342 staining. We also found that Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] treatment resulted in down-regulation of Bcl-2 as well as up-regulation of Bax expression, whereas treatment with ALA up-regulated the level of Bcl-2/Bax protein expression. These results demonstrated that ALA could attenuate Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] -induced neuronal apoptosis by preventing amyloidogenic APP processing.
Since a bioconversion of ALA to DHA is very limited, dietary intake of ALA has been little focused on brain health compared to supplementation with EPA/DHA. However, plant-derived ALA represents more sustainable sources of omega-3 fatty acids and exerts identical effects as DHA in various physiological processes [51] . There are evidences that ALA is a potent neuroprotective agent against ischemia in animal models and ALA plays a protective role from stroke risk [52, 53] . In addition, ALA protected neuronal death against glutamate toxicity [54] . Furthermore, it has been indicated that dietary ALA-enriched perilla oil and EPA/DHA-enriched fish oil exert similar physiological activity [55] . Our previous study also demonstrated that ALA administration improved cognitive ability through APP processing in Ab-injected AD mice model, comparable to DHA [56] , suggesting that ALA may independently or directly contribute to brain health.
In summary, our findings suggest that ALA from perilla oil increased cell viability and decreased LDH release against Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] treatment. In addition, ALA attenuated Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] -induced ROS production via regulation of MAPK signaling as indicated by down-regulation of ERK1/2 and JNK phosphorylation. These functions are associated with inhibition of the amyloidogenic pathway and promotion of the non-amyloidogenic pathway, leading to the reduction of Ab deposits. Moreover, ALA treatment prevented neuronal apoptosis through the up-regulation of Bcl-2/Bax protein expression ratio. Therefore, ALA may serve as a useful therapeutic agent for prevention of AD progression.
